title: Cellular immune responses to HPV-18, -31, and -53 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles.
abstract: Human papillomavirus-like particles (HPV VLP) are candidate vaccines that have shown to be efficacious in reducing infection and inducing robust antiviral immunity. Neutralizing antibodies generated by vaccination are largely type-specific, but little is known about the type-specificity of cellular immune responses to VLP vaccination. To determine whether vaccination with HPV-16 L1VLP induces cellular immunity to heterologous HPV types (HPV-18, HPV-31, and HPV-53), we examined proliferative and cytokine responses in vaccine (n=11) and placebo (n=5) recipients. Increased proliferative and cytokine responses to heterologous types were observed postvaccination in some individuals. The proportion of women responding to heterologous types postvaccination (36%-55%) was lower than that observed in response to HPV-16 (73%). Response to HPV-16 VLP predicted response to other types. The strongest correlations in response were observed between HPV-16 and HPV-31, consistent with their phylogenetic relatedness. In summary, PBMC from HPV-16 VLP vaccine recipients can respond to L1VLP from heterologous HPV types, suggesting the presence of conserved T cell epitopes.
authors.affiliation: HPV Immunology Laboratory, SAIC-Frederick, Inc./NCI-Frederick, Frederick Building 469, Room 120, Frederick, MD 21702, USA.
authors.forename: Ligia A
authors.initials: LA
authors.lastname: Pinto
authors.forename: Raphael
authors.initials: R
authors.lastname: Viscidi
authors.forename: Clayton D
authors.initials: CD
authors.lastname: Harro
authors.forename: Troy J
authors.initials: TJ
authors.lastname: Kemp
authors.forename: Alfonso J
authors.initials: AJ
authors.lastname: García-Piñeres
authors.forename: Matthew
authors.initials: M
authors.lastname: Trivett
authors.forename: Franklin
authors.initials: F
authors.lastname: Demuth
authors.forename: Douglas R
authors.initials: DR
authors.lastname: Lowy
authors.forename: John T
authors.initials: JT
authors.lastname: Schiller
authors.forename: Jay A
authors.initials: JA
authors.lastname: Berzofsky
authors.forename: Allan
authors.initials: A
authors.lastname: Hildesheim
mesh_terms: D000293:Adolescent; D000328:Adult; D000956:Antigens, Viral / Q000276:immunology; D036022:Capsid Proteins / Q000235:genetics / Q000276:immunology*; D049109:Cell Proliferation; D016207:Cytokines / Q000096:biosynthesis; D005260:Female; D006801:Humans; D007273:Injections, Intramuscular; D007963:Leukocytes, Mononuclear / Q000276:immunology*; D008214:Lymphocytes / Q000276:immunology*; D009856:Oncogene Proteins, Viral / Q000235:genetics / Q000276:immunology*; D027383:Papillomaviridae / Q000235:genetics / Q000276:immunology*; D030361:Papillomavirus Infections / Q000097:blood / Q000276:immunology*; D011994:Recombinant Proteins / Q000276:immunology; D013045:Species Specificity; D002583:Uterine Cervical Neoplasms / Q000097:blood / Q000276:immunology*; D014611:Vaccination; D014614:Vaccines, Synthetic / Q000008:administration & dosage / Q000276:immunology; D014765:Viral Vaccines / Q000008:administration & dosage / Q000276:immunology*
chemical_list: D000956:Antigens, Viral; D036022:Capsid Proteins; D016207:Cytokines; D009856:Oncogene Proteins, Viral; D011994:Recombinant Proteins; D014614:Vaccines, Synthetic; D014765:Viral Vaccines; C063317:L1 protein, Human papillomavirus type 16